Schering/Migenix Sign Deal For PEG-Intron Hepatitis C Combo Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough gains right to negotiate a licensing agreement for Migenix’ hepatitis C therapy celgosivir (MX-3253). Schering will provide pegylated interferon alfa-2b and ribavirin to Migenix for a Phase II combination study.
You may also be interested in...
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.
US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.